These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23208355)

  • 21. Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.
    Bennouna J
    Future Oncol; 2017 Sep; 13(21):1829-1833. PubMed ID: 28657354
    [No Abstract]   [Full Text] [Related]  

  • 22. Medicine. Why a new cancer drug works well, in some patients.
    Marx J
    Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
    [No Abstract]   [Full Text] [Related]  

  • 23. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
    Jones S
    Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
    [No Abstract]   [Full Text] [Related]  

  • 24. [Genomic approaches to tailored therapy in non-small cell lung cancer].
    Song Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Dec; 31(12):889-90. PubMed ID: 19134403
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeting EGFR in non-small-cell lung cancer.
    Doroshow JH
    N Engl J Med; 2005 Jul; 353(2):200-2. PubMed ID: 16014890
    [No Abstract]   [Full Text] [Related]  

  • 26. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
    Lai RS; Xie L; Shen LS; He YM; Zhu CL
    Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324
    [No Abstract]   [Full Text] [Related]  

  • 27. DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients.
    Nogueira A; Assis J; Catarino R; Medeiros R
    Pharmacogenomics; 2013 Apr; 14(6):689-700. PubMed ID: 23570471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR mutations in non-small-cell lung cancer.
    Hung JJ; Jeng WJ; Hsu WH; Liu JS; Wu YC
    Lancet Oncol; 2010 May; 11(5):412-3; author reply 413. PubMed ID: 20434712
    [No Abstract]   [Full Text] [Related]  

  • 29. EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
    Winther Larsen A; Nissen PH; Meldgaard P; Weber B; Sorensen BS
    Lung Cancer; 2014 Sep; 85(3):435-41. PubMed ID: 25017413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
    Costa DB; Kobayashi S
    Br J Cancer; 2007 Jan; 96(2):399; author reply 400. PubMed ID: 17224926
    [No Abstract]   [Full Text] [Related]  

  • 31. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 32. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
    Garfield D
    Lung Cancer; 2006 Jun; 52(3):373. PubMed ID: 16621130
    [No Abstract]   [Full Text] [Related]  

  • 33. Smokers have 10 times more genetic damage in lung cancer tumors.
    Cancer; 2013 Jan; 119(2):248-9. PubMed ID: 23292898
    [No Abstract]   [Full Text] [Related]  

  • 34. Expanding targeted therapies for NSCLC.
    Cancer Discov; 2014 Dec; 4(12):OF1. PubMed ID: 25477108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
    Gandara DR; Lara PN; Mack P; Scagliotti G
    Clin Lung Cancer; 2009 May; 10(3):148-50. PubMed ID: 19443333
    [No Abstract]   [Full Text] [Related]  

  • 36. Chasing mutations in the epidermal growth factor in lung cancer.
    Dowell JE; Minna JD
    N Engl J Med; 2005 Feb; 352(8):830-2. PubMed ID: 15728818
    [No Abstract]   [Full Text] [Related]  

  • 37. [I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].
    Urata Y; Satouchi M
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):931-4. PubMed ID: 26353389
    [No Abstract]   [Full Text] [Related]  

  • 38. The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.
    Langer CJ
    J Clin Oncol; 2009 Mar; 27(9):1350-4. PubMed ID: 19224840
    [No Abstract]   [Full Text] [Related]  

  • 39. EGFR mutation and response of lung cancer to gefitinib.
    Toyooka S; Kiura K; Mitsudomi T
    N Engl J Med; 2005 May; 352(20):2136; author reply 2136. PubMed ID: 15901872
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
    Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P
    Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.